Integrating Routine PsA Structural Assessments in Clinical Practice: The Time Is Now!

Integrating Routine PsA Structural Assessments in Clinical Practice: The Time Is Now!

Integrating Routine PsA Structural Assessments in Clinical Practice: The Time Is Now!

It can be difficult to effectively integrate monitoring of PsA structural progression into clinical practice. Learn how to overcome common barriers.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Routine assessment of psoriatic arthritis (PsA)-related structural progression has often proven challenging to integrate into clinical practice. Nonetheless, the imperative is clear as frequent monitoring of PsA structural progression permits earlier intervention with effective therapies and can support clinical decisions to switch to another class of agent. This ECHO offers insights from Drs. Sergio Schwartzman, Philip Mease, and April Armstrong concerning which therapeutic agents have been shown to impact PsA structural progression in clinical trials, as well as guidance on how best to incorporate collaborative treatment strategies across disciplines. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Sergio Schwartzman, MD
    Franchellie M. Cadwell Chair Emeritus, Hospital for Special Surgery
    Clinical Associate Professor of Medicine, Weill Cornell Medical Center
    Associate Attending Physician, New York Presbyterian Hospital
    Associate Attending Physician, Hospital for Special Surgery
    New York, NY

    Consulting Fees: AbbVie, Janssen, Jubilant, Lilly, Myriad, Novartis, Pfizer, Regeneron, Sanofi, Stelexis, Teijin, UCB

    April Armstrong, MD
    Professor of Dermatology and Associate Dean for Clinical Research
    Keck School of Medicine of USC
    Los Angeles, CA

    Research: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, Dermavant, Dermira, EPI, Incyte, Janssen, LEO, Lilly, ModMed, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun, UCB
    Consulting Fees: AbbVie, ASLAN, BI, BMS, Dermavent, Dermira, EPI, LEO, Incyte, Janssen, Lilly, Novartis, Ortho Dermatologics, Sanofi, Sun, Regeneron, UCB

    Philip Mease, MD
    Director, Division of Rheumatology Clinical Research
    Swedish Medical Center/Providence St. Joseph Health
    Clinical Professor, School of Medicine, University of Washington
    Seattle, WA

    Research: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun, UCB
    Consulting Fees: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sun, UCB

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Stephen Chavez has nothing to disclose.
    • Jay Runyon has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe ways to evaluate the progression of structural damage in psoriatic arthritis (PsA)
    • Identify clinical trials in which PsA-related structural damage was assessed
    • Assess therapies for PsA based on their safety and efficacy in decreasing structural damage
    • Formulate strategies to minimize radiographic progression of PsA and maximize patient quality of life
  • Target Audience

    This activity is designed to meet the educational needs of healthcare professionals specializing in PsA, including rheumatologists, dermatologists, and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 30-minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Lilly USA, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free